Swiss Biotech Merger: Bones + Oncology + Vaccines?

20/01/2016 - 2 minutes

Kuros Biosurgery in Zürich (Switzerland), the bone remodelling biotech for trauma patients, today officially acquired Cytos Biotechnology in Schlieren, the two of which are now to be rebranded ‘Kuros Biosciences’ in a Swiss Stock Exchange merger. 
logo_kuros_biosciences_cytos_biotechnologyKuros is developing innovative products for tissue repair and regeneration. The company is a spin-off of the Swiss Federal Institute of Technology (ETH Zurich) and is focused in the areas of medical sealants and bone healing (orthobiologics).

This comes after a €18M (CHF20M) financing of Kuros in November, allowing the Zurich biotech to expand its financial horizons and grow, with sights set on the SIX Swiss Exchange and Cytos.

So what does Cytos bring to the new Kuros Brand?

Well, its infectious disease platforms for viruses such as Hepatitis B are certainly a major draw, several faculties of which are already tied up in partnerships and therefore earning Cytos (now Kuros) a steady income.

One example is Cytos’ clinically validated its virus-like particle (VLP) platform,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!